2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

May 20, 2021

Press Releases

2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

 Copenhagen — May 20, 2021 — 2cureX announces that the outcome of the clinical trial (NCT03251612, TICC) is published by ASCO (https://meetinglibrary.asco.org/record/198560/abstract) prior to its Annual Meeting in June 2021. The primary endpoint of the trial was met.

The patients enrolled in the trial suffered from end stage metastatic colorectal cancer and had IndiTreat®-guided third line treatment selected from a panel of 15 drug regimen. They comprised standard cytostatics and other cancer drugs with proven effect in clinical trials.  The primary endpoint was Progression Free Survival (PFS) after 8 weeks of treatment. PFS of placebo arms in randomized last-line trials is 20% and the success criterion of the present trial was set at 40%.

90 patients were enrolled in the trial, 82 underwent biopsy from liver metastases of which 44 (54%) succeeded in producing microtumors which could be IndiTreat® drug screened with identification of at least one possible treatment. Thirty-four patients were treated in accordance with the test result and 17 (50%) obtained PFS after 8 weeks.  The median PFS of patients undergoing IndiTreat®-guided third line treatment was 81 days and median overall survival (OS) was 189 days.

Henrik Harling, Chief Medical Officer, 2cureX: “We are very satisfied with the result of this study in a fragile group of end stage cancer patients. They are difficult to treat in daily practice because the guideline recommendations have been exhausted and they are facing a gloomy prognosis and rapidly declining quality of life. Using the IndiTreat® test for selection of treatment, the disease remained under control for 2 months in half of the patients and survival without progression of the cancer lasted nearly 3 months. This is of great value for patients who, despite incurable disease, still have the courage and desire for treatment. The successful identification of the most effective treatment from a panel of cancer drugs which have already been on the market for a long time, also speaks in favour of the IndiTreat® test. It is our hope that the test will now become a routine tool in hospitals that makes it possible to live longer and better with incurable colorectal cancer”.

For more information:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient’s tumor and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”). For more information about 2cureX visit www.2cureX.com. Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se.